Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00241540 · ClinicalTrials.gov registry record · Phase 3
Esomeprazole for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 808
- Enrollment target
NCT00241540 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 808 participants.
The verdict
NCT00241540, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 808 participants
- Enrollment target
Study Summary
This study is a randomised, double-blind, parallel-group and placebo controlled study comparing the efficacy of esomeprazole 40 mg orally qd vs. placebo and esomeprazole 20 mg orally qd vs. placebo when given to patients on continuous use of NSAIDs, including COX-2 selective NSAIDs, for a period of 4 weeks in treatment of relief of upper GI symptoms.
Interventions
- DRUG Esomeprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 808 participants |
| Start Date | 2001-01 |
| Est. Completion | 2002-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00241540
The ClinicalTrials.gov registry entry for NCT00241540 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 808 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Esomeprazole is the first listed.
NCT00241540 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00241540 about?
NCT00241540 is a clinical study titled "Esomeprazole for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs". This study is a randomised, double-blind, parallel-group and placebo controlled study comparing the efficacy of esomeprazole 40 mg orally qd vs. placebo and esomeprazole 20 mg orally qd vs. placebo when given to patients on continuous use of NSAIDs, including COX-2 selective NSAIDs, for a period of ...
What is the current status of trial NCT00241540?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 808 participants. The study started on 2001-01. Estimated completion is 2002-08.
What interventions are being tested in trial NCT00241540?
The interventions under investigation include: Esomeprazole (DRUG).
Who is sponsoring clinical trial NCT00241540?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.